Cancer clinics currently use high-dose stereotactic body radiation therapy as a curative treatment for several kinds of cancers. However, the contribution of vascular endothelial cells to tumor response to radiation remains controversial. Using dual recombinase technology, we generated primary sarcomas in mice with targeted genetic mutations specifically in tumor cells or endothelial cells. We selectively mutated the proapoptotic gene Bax or the DNA damage response gene Atm to genetically manipulate the radiosensitivity of endothelial cells in primary soft tissue sarcomas. Bax deletion from endothelial cells did not affect radiation-induced cell death in tumor endothelial cells or sarcoma response to radiation therapy. Although Atm deletion increased endothelial cell death after radiation therapy, deletion of Atm from endothelial cells failed to enhance sarcoma eradication. In contrast, deletion of Atm from tumor cells increased sarcoma eradication by radiation therapy. These results demonstrate that tumor cells, rather than endothelial cells, are critical targets that regulate sarcoma eradication by radiation therapy. Treatment with BEZ235, a small-molecule protein kinase inhibitor, radiosensitized primary sarcomas more than the heart. These results suggest that inhibiting ATM kinase during radiation therapy is a viable strategy for radiosensitization of some tumors.
INTRODUCTION
About half of all cancer patients are treated with radiation therapy (1), which may be given with palliative intent in cases where a delay in tumor regrowth (growth delay) can be clinically meaningful. However, the majority of cancers treated with radiation therapy are treated with the intent to cure, where the goal of radiation therapy is to achieve complete and permanent tumor regression (local control). When patients with cancer are treated with radiation, they usually receive relatively small (1.8 to 2.0 Gy) daily fractions for 1 to 2 months. Recently, advances in radiation treatment planning and delivery have made it possible to safely deliver a small number of high radiation doses (15 to 24 Gy), termed stereotactic body radiation therapy (SBRT) or radiosurgery, to improve the local control of some tumors (2).
The tumor microenvironment of human cancers consists of blood vessels, fibroblasts, and immune cells that modulate cancer development, progression, and response to therapy (3). However, whether or not stromal cells, such as endothelial cells, are critical targets of radiation therapy remains controversial. Indeed, experiments using transplanted tumors in mice with radiosensitive stroma have suggested that tumor stromal cells do not contribute to local control of cancer by radiation therapy (4) .
Recently, endothelial cell apoptosis and microvascular collapse were reported to contribute to the radiation response of transplanted melanoma and fibrosarcoma cell lines (5) . Endothelial cell apoptosis can occur because of membrane damage, which triggers rapid ceramidemediated apoptosis after high doses of radiation exposure (6, 7) . As a result, transplanted tumors with acid sphingomyelinase-or Bcl-2-associated X protein (Bax)-deficient stroma, which have defective radiation-induced endothelial cell apoptosis, grow 200 to 400% faster than transplanted tumors with wild-type stroma and display a decreased growth delay after radiation doses of up to 20 Gy (5) . Notably, endothelial cell apoptosis has been proposed to occur at a threshold of 8 to 10 Gy and to increase up to 20 to 25 Gy (7), suggesting that endothelial apoptosis may be contributing to tumor cure by SBRT (8) . However, the conclusion that microvascular damage regulates tumor response to radiation has been challenged (9, 10) , and additional experiments using transplanted model systems have failed to resolve the controversy (11) (12) (13) (14) .
Unlike transplanted tumor models, which may not fully recapitulate the vasculature and immune surveillance of autochthonous tumors (15, 16) , genetically engineered mouse models (GEMMs) develop tumors within the native microenvironment in immunocompetent mice (17) and may more faithfully recapitulate the tumor stroma and microenvironment of human cancers (18) . In addition, the response of these primary mouse cancer models to therapeutics might mimic the response of human cancers in clinical trials (19, 20) .
To investigate the contribution of endothelial cells to the radiation response of primary sarcomas, we developed the technology to contemporaneously mutate different genes specifically in the tumor cells versus the endothelial cells of primary sarcomas (21) . In this system, an adenovirus expressing FlpO (adeno-FlpO) activates a conditional allele of oncogenic Kras (FSF-Kras
G12D
) and deletes both copies of a conditional allele of p53 (p53 FRT ), whereas a tissue-specific Cre driver mutates floxed alleles specifically in endothelial cells. We recently used this dual recombinase technology to demonstrate that selectively sensitizing endothelial cells to mitotic cell death by deleting the DNA damage response gene ataxia telangiectasia mutated (Atm) (22) prolongs sarcoma growth delay after SBRT (23) . However, an increase in growth delay does not necessarily translate into improved local control (4, 24, 25).
Here, we irradiated sarcomas with Atm deleted in endothelial cells with a curative dose of radiation. We also used dual recombinase technology to selectively protect endothelial cells from apoptosis by deleting the proapoptotic gene Bax (26) . We found that tumor endothelial cells in primary sarcomas did not die via apoptosis within four hours of SBRT. In addition, endothelial cell death did not contribute to sarcoma eradication by radiation therapy. In contrast, radiosensitizing tumor cells by deleting Atm increased local control of primary sarcomas after radiation therapy. These results demonstrate that tumor cells, but not endothelial cells, are critical targets of curative radiation therapy in primary sarcomas. Also, to test whether ATM inhibition can improve the therapeutic ratio during SBRT, we compared the radiation response of primary sarcomas and hearts after Atm inhibition with BEZ235 to demonstrate that targeting ATM during radiation therapy might be a viable approach for radiosensitization of tumors at certain anatomic sites. mice with a single dose of 20 Gy using fluoroscopy-guided radiation therapy and examined endothelial cell death through terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nickend labeling (TUNEL) staining at various time points after irradiation.
RESULTS
In transplanted tumor models, tumor endothelial cell apoptosis peaks 4 to 6 hours after radiation exposure (5). Consistent with our previous results (23), we did not observe a significant change in apoptotic endothelial cell death 4 hours after irradiation of primary sarcomas, but endothelial cell death did increase 48 hours after radiation, likely as a result of mitotic catastrophe (Fig. 1, A FL/FL mice with 50 Gy, which we determined to be the maximally tolerated dose in our system. Although 50 Gy was able to eradicate a small percentage of primary sarcomas, there was no difference in local control or growth delay between the two genotypes ( Fig. 1E  and fig. S2 ).
Because the proapoptotic genes Bax and Bcl-2 homologous antagonist/ killer (Bak) can be redundant for executing programmed cell death in some settings (29) mice died of unknown causes at 7 and 10 weeks after irradiation with four daily fractions of 20 Gy before sarcoma tripling. Thus, these mice were scored as locally controlled until the time points at which they either developed metastasis or died. Log-rank tests showed that the differences were not statistically significant. Asterisks represent statistically significant difference between the indicated groups. Atm FL/FL mice after irradiation with 50 Gy (n = 13 mice per group). Several mice were euthanized before sarcoma tripling because of the development of second sarcomas at other locations in the body, presumably from systemic tamoxifen-mediated Cre recombination. These mice were scored as locally controlled until the time point of second tumor formation. Log-rank test, P < 0.05. Asterisks represent statistically significant difference between the indicated groups.
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The protein kinase inhibitor BEZ235 preferentially radiosensitizes primary sarcomas Deletion of the Atm gene from tumor cells increased the probability of tumor eradication after SBRT, suggesting that therapeutic targeting of the ATM protein could improve tumor response to radiation therapy. However, systemic targeting of ATM in normal tissues might also increase radiation toxicity. To begin to address whether targeting ATM during radiation therapy can improve the response of tumors relative to some normal tissues (that is, to enhance the therapeutic ratio), we showed recently that deleting Atm preferentially radiosensitizes proliferating tumor endothelial cells compared with quiescent heart endothelial cells (23) . Here, we used a pharmacological approach to investigate whether a therapeutic window exists for inhibiting ATM during radiation therapy. To this end, we treated KP loxP mice that had primary sarcomas with the phosphoinositide 3-kinase (PI3K)-like kinase (PI3KK) inhibitor BEZ235, which potently inhibits human ATM (35) . Pretreatment of the mice with BEZ235 significantly decreased autophosphorylation of mouse Atm and phosphorylation of the Atm target Kap1 (Krüppel-associated box-associated protein 1) in primary sarcomas after irradiation with 20 Gy (fig. S8, A to D) .
To investigate whether BEZ235 can selectively radiosensitize sarcomas, we collected hearts and primary sarcomas from vehicle-and BEZ235-treated KP loxP mice 24 hours after whole-body irradiation with 20 Gy. Treatment with BEZ235 significantly increased cell death in sarcomas but not in hearts (Fig. 4, A and B) . Next, we monitored tumor growth in KP loxP mice treated with BEZ235 alone or in combination with focal 20 Gy irradiation. Although a single dose of BEZ235 alone did not delay tumor growth ( fig. S8 , E and F), BEZ235 treatment significantly delayed primary sarcoma regrowth after 20 Gy (Fig. 4, C  and D) .
We next investigated the effect of BEZ235 treatment on the development of radiation-induced heart disease. We showed previously that deletion of Atm radiosensitizes p53-null cardiac endothelial cells but not cardiac endothelial cells with intact p53 (23 ) mice with two alleles of p53 deleted in endothelial cells with either vehicle or BEZ235 2 hours before whole-heart irradiation with 12 Gy and monitored the mice for the development of radiation-induced heart disease. BEZ235 shifted the myocardial necrosis-free survival curve to the left in VP FL/FL mice but did not promote the development of radiationinduced myocardial necrosis in VP FL/+ mice (Fig. 4E) . Because we used BEZ235 with a single dose of radiation, we cannot exclude the possibility that ATM inhibition has some effect on radiation-induced heart disease with other radiation doses. However, taken together with the genetic studies, these experiments with a pharmacological inhibitor of ATM suggest that inhibiting ATM may preferentially radiosensitize sarcomas compared with quiescent normal tissues, such as the heart.
DISCUSSION
Here, we used a new dual recombinase technology to manipulate the radiosensitivity of endothelial cells in primary sarcomas. In contrast to results with transplanted tumor models (5), we found that tumor endothelial cells in primary sarcomas did not die via apoptosis within ), both of which were treated with vehicle or BEZ235 (50 mg/kg) 2 hours before whole-heart irradiation with 12 Gy (n = 7 to 9 mice per group). 4 hours after irradiation. Although endothelial cells can contribute to primary sarcoma growth delay after noncurative radiation therapy (23) , radiosensitizing endothelial cells did not increase local control. In contrast, radiosensitization of tumor cells increased the probability of sarcoma eradication by SBRT. Therefore, tumor cells, but not endothelial cells, are critical targets of SBRT that mediate sarcoma eradication.
These results have important clinical implications, suggesting that increased endothelial cell death does not contribute to the improved local control of some tumors after SBRT. Instead, the increased efficacy of SBRT is likely the result of delivering larger, biologically effective doses than are delivered with standard radiation therapy (36) . Our results are consistent with the previous observation that local control is not affected when tumors are transplanted into radiosensitive mice (4) and extend these findings to primary sarcomas. Despite the extensive endothelial cell death observed after a dose of 50 Gy (Fig. 2, A and B) , most of the sarcomas in KP FRT VAtm FL/FL mice recurred (Fig. 2C) . These results raise the possibility that the vasculature in recurrent sarcomas may have come from outside of the irradiation field (37) . Although the source of these newly formed blood vessels remains an area of ongoing debate (38) , targeting vascular recruitment could improve local control.
Our results do not exclude a contribution from other stromal cells to tumor eradication with SBRT. Indeed, recent studies suggest that the recruitment of macrophages from outside the radiation field through a stromal cell-derived factor 1 (SDF-1)-C-X-C chemokine receptor 4 (CXCR4) axis might participate in tumor cell repopulation after radiotherapy (37) . In addition, a growing body of data suggests that the immune system can contribute to the killing of tumor cells after radiation therapy (39, 40) , and this response may be greater after SBRT than after standard radiation therapy. Furthermore, our experiments focused on soft tissue sarcomas, and additional experiments are needed to determine whether endothelial cell death contributes to the radiation response of other tumor types. In the future, dual recombinase technology can be applied to other primary tumor model systems and stromal cell populations to further explore how the tumor microenvironment contributes to curative radiation therapy.
Although most patients are treated with curative intent, for patients receiving palliative radiation therapy, an increased growth delay can be clinically meaningful. For example, radiation therapy is the standard of care for children with diffuse intrinsic brainstem gliomas and provides many months of relief from severe neurological symptoms (41) . Targeting tumor endothelial cells during radiation therapy could prolong the time that these patients remain neurologically intact. However, our results suggest that this approach may not improve tumor eradication. Instead, targeting tumor cells with radiosensitizers, such as inhibitors of ATM, might be a more promising treatment approach to achieve local control.
MATERIALS AND METHODS
Study design
The goal of this controlled laboratory experiment was to determine the relative contribution of endothelial cells and tumor cells to primary sarcoma response to radiation therapy. We used genetically engineered mice and observed histological, growth delay, and local control endpoints. Sample sizes were selected before initiating the study on the basis of prior primary sarcoma radiation response data from the laboratory and power calculations performed as described previously (42) ; data collection was stopped if a smaller sample size achieved statistical significance. Outliers were defined before initiating the study as falling greater than 2 SD from the mean. No outliers were excluded from this study. Sarcoma eradication was assumed if a sarcoma failed to triple in size 18 weeks after radiation treatment. Assuming a constant sarcoma doubling time of 4 days and tumor cell diameter of 25 mm (volume = 8.18 × 10 −6 mm 3 ), it would take a single tumor cell 100 days (~14 weeks) to reach 300 mm 3 . Mice that died before sarcoma tripling as a result of metastasis or sarcoma development at a distant site were censored at the time of death and were scored as locally controlled until this point. The mice in this study were not randomized to their treatments and were selected based on availability. The investigators were not blinded when performing sarcoma measurements. Histological quantification was performed by an observer blinded to treatment and genotype. Histological assessment of residual sarcoma cells in the legs of irradiated mice was assessed by a sarcoma pathologist (D.M.C.) who was blinded to treatment and genotype.
Mouse strains and sarcoma induction All animal studies were performed in accordance with protocols approved by the Duke University Institutional Animal Care and Use Committee. All of the mouse strains used in this study have been described previously, including LSL-Kras FRT mice between 6 and 10 weeks of age as described previously (21, 47) . Tamoxifen-induced primary sarcomas were generated by injecting 50 ml of 4-hydroxytamoxifen (5 mg/ml; Sigma-Aldrich) in dimethyl sulfoxide into the right hind leg of P7KP loxP mice (48) . All mice were on a mixed genetic background. To minimize the effect of genetic background, age-matched littermate controls were used for every experiment so that potential genetic modifiers would be randomly distributed between the experimental and control groups.
Radiation treatment
Sarcoma and whole-heart irradiations were performed using the X-RAD 225Cx small animal image-guided irradiator (Precision X-Ray). The irradiation field was centered on the target via fluoroscopy with 40 kilovolt peak (kVp), 2.5 mA x-rays using a 2-mm aluminum filter. Sarcomas were irradiated with parallel-opposed anterior and posterior fields with an average dose rate of 300 cGy/min prescribed to midplane with 225 kVp, 13 mA x-rays using a 0.3-mm copper filter and a collimator with a 40 × 40 mm 2 radiation field at treatment isocenter. Whole-heart irradiation was performed using a collimator to produce a 15-mm circular radiation field at treatment isocenter. Dose rates were measured with an ion chamber by the Radiation Safety Division at Duke University. Sarcomas were irradiated at~250 mm 3 by caliper measurement for growth delay and histological endpoints and 100 mm 3 for local control endpoints. After sarcoma irradiation, sarcomas were measured three times per week for growth delay and once per week for local control experiments until they tripled in size from the initial volume measured at the time of radiation. After whole-heart irradiation, mice were monitored daily for symptoms of heart disease. Myocardial necrosis was confirmed histologically by hematoxylin and eosin (H&E) staining of heart sections.
Histological analysis H&E was performed on paraffin-embedded tissue sections. Tissue specimens were fixed in 10% neutralized formalin overnight and preserved in 70% ethanol until paraffin embedding. Five micron sections were deparaffinized with xylene and rehydrated with a graded series of ethanol and water washes before performing H&E staining. Sarcoma and heart immunohistochemistry was performed on frozen tissue sections. Specimens were embedded directly in optimal cutting temperature compound (Sakura Fintek) by snap freezing in a dry ice/isopentane slurry and stored at −80°C until sectioning. Ten-micrometer sections were fixed in 4% paraformaldehyde before immunofluorescence staining. The primary antibodies were rat anti-mouse CD31 (1:250; BD Pharmingen, #553370), rabbit anti-mouse Ser 
Flow sorting of endothelial cells
Lungs were dissected, washed in phosphate-buffered saline, homogenized, and digested in type I collagenase (0.8 mg/ml; Worthington Biochemical Corp.) for 1 hour at 37°C. Digested tissues were filtered, and red blood cells were lysed with ACK lysing buffer (Lonza Group). Total number of cells was counted by Coulter counter (Beckman Coulter Inc.). Three million cells were stained with phycoerythrin (PE)-conjugated anti-mouse CD31 (BioLegend, #102407), PE-Cy5-conjugated anti-mouse CD45 (eBioscience, #15-0451), and eFluor 660-conjugated anti-mouse CD34 (eBioscience, #50-0341) antibodies. Dead cells were excluded by staining with 7-aminoactinomycin D (BD Pharmingen). Viable CD45-negative and CD31 and CD34 doublepositive cells were sorted by FACSVantage (BD Pharmingen) and used for RNA isolation.
Quantitative reverse transcription PCR analysis Total RNA was extracted from sorted lung and tumor endothelial cells with the RNAqueous-Micro Kit (Ambion), and reverse transcription was performed with the iScript complementary DNA (cDNA) Synthesis Kit (Bio-Rad). Quantitative reverse transcription PCR was performed using TaqMan Universal PCR Master Mix (Applied Biosystems) and TaqMan Gene Expression Assay Mix (Applied Biosystems) for Bax (Mm00432050_m1) or Hprt (Mm0446968_m1). Hprt was used as an internal control to correct for the concentration of cDNA in different samples. Each experiment was performed with three replicates from each sample, and the results were averaged.
Cell line experiments and clonogenic survival assays Cell lines were isolated by digestion of primary sarcomas with trypsin, type IV collagenase, and dispase (Invitrogen). Cells were cultured in Dulbecco's modified Eagle's medium with high glucose and pyruvate (Gibco) supplemented with 10% fetal bovine serum. Cells were passaged five times to deplete stromal cells before isolation of genomic DNA for PCR or clonogenic survival assays. Deletion of Atm was verified by PCR using primers flanking the 3′ loxP site (sense, 5′-GGGCTAC-GAAATGAGACACACAC-3′; antisense 5′-CTTCCCCTGTTCAA-AAGCCACTC-3′) and primers flanking the recombined loxP site (sense, 5′-TGAGTTCAAATCCCAGGAGCCAG-3′; antisense, 5′-CTTCCCCT-GTTCAAAAGCCACTC-3′). For clonogenic survival assays, cells were plated in triplicate and allowed to adhere overnight before irradiation with an X-RAD 320 Biological Irradiator (Precision X-Ray). Cells were placed 50 cm from the radiation source and were irradiated with a dose rate of 161 cGy/min using 320 kVp, 10 mA x-rays and a 2-mm aluminum filter. After development of colonies, cells were fixed with 70% ethanol, stained with Coomassie Brilliant Blue (Bio-Rad), rinsed with deionized water, and dried. A population of more than 50 cells was counted as one colony, and surviving fractions were calculated relative to unirradiated controls.
BEZ235 treatment
Mice were treated by oral gavage with a single dose of BEZ235 (50 mg/kg; Novartis) dissolved in 10% N-methyl-2-pyrrolidone/90% polyethylene glycol 300 (Sigma-Aldrich) 2 hours before radiation therapy.
Statistics
Results are presented as means ± SEM. Two-tailed Student's t test was performed to compare the means of two groups. Two-way ANOVA was performed to examine the interaction between genotypes and treatments followed by Bonferroni's post hoc tests for pairwise comparisons of individual treatments or genotypes. Non-normally distributed data were log-transformed before applying statistical tests. For survival studies, Kaplan-Meier analysis was performed followed by log-rank test for statistical significance. Significance was assumed at P < 0.05. All calculations were performed using Prism 5 (GraphPad).
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www.sciencetranslationalmedicine.org/cgi/content/full/7/278/278ra34/DC1 Fig. S1 . Deletion of Bax in primary tumor endothelial cells does not affect sarcoma initiation or growth. Fig. S2 . Deletion of Bax in endothelial cells does not affect sarcoma growth delay after a curative dose of irradiation. 
